❓WHAT HAPPENED: President Donald J. Trump has cut a deal to lower the price of certain weight loss drugs.
👤WHO WAS INVOLVED: President Trump, Eli Lilly, and Novo Nordisk officials.
📍WHEN & WHERE: The announcement was made on Thursday.
💬KEY QUOTE: “This is a triumph for American patients that will save lives and improve the health of millions and millions of Americans,” Trump said.
🎯IMPACT: The deal is expected to lower the price of obesity drugs to $149 per month in certain cases.
President Donald J. Trump has cut a deal to bring down prices for select weight loss medications. “This is a triumph for American patients that will save lives and improve the health of millions and millions of Americans,” he said during an Oval Office announcement on Thursday.
The America First leader noted that, “Until now, [GLP-1 drugs] have [not] been covered by Medicare for weight loss and they’ve only rarely been covered by Medicaid,” stressing: “They’ve often cost consumers more than $1,000 per month, and some a lot more than that. Americans have been spending as much as 520 percent for Zepbound and 1,400 percent more for Wegovy than patients in Europe.”
The pact, which includes drugmakers Eli Lilly and Novo Nordisk, aims to reduce the monthly cost of obesity treatments to $149 under certain conditions. “Today marks a pivotal moment in U.S. health care policy and a defining milestone for Lilly, made possible through collaboration with the Trump administration,” commented Eli Lily chairman David A. Ricks. “As we expand access to obesity treatments for more Americans and advance one of the most innovative obesity pipelines, we remain focused on improving outcomes, strengthening the U.S. health care system, and contributing to the health of our nation for generations to come,” he added.
“Novo Nordisk has always worked to secure affordable access to our innovative medicines, and today’s announcement will bring semaglutide medicines to more American patients at a lower cost, Importantly, this also expands obesity medication access in Medicare, which will allow people living with obesity to access authentic Wegovy,” concurred Novo Nordisk president Mike Doustdar.
Join Pulse+ to comment below, and receive exclusive e-mail analyses.